First-line bevacizumab contributes to survival improvement in glioblastoma patients complementary to temozolomide
Nobuhiro Hata, Masahiro Mizoguchi, Daisuke Kuga, Ryusuke Hatae, Yojiro Akagi, Yuhei Sangatsuda, Takeo Amemiya, Yuhei Michiwaki, Yutaka Fujioka, Kosuke Takigawa, Satoshi O. Suzuki, Tadamasa Yoshitake, Osamu Togao, Akio Hiwatashi, Koji Yoshimoto, Koji Iihara
Topics & Concepts
TemozolomideBevacizumabMedicineOncologyInternal medicineGlioblastomaProportional hazards modelChemotherapyCancer researchGlioma Diagnosis and TreatmentBrain Metastases and TreatmentPARP inhibition in cancer therapy